anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Catheter-directed thrombolysis is one of the main treatments for acute limb ischaemia. Urokinase is still a widely used thrombolytic drug in some regions. However, there needs to be a clear consensus on the protocol of continuous catheter-directed thrombolysis using urokinase for acute lower limb ischaemia.
METHODS: A single-centre protocol of continuous catheter-directed thrombolysis with low-dose urokinase (20,000 IU/hour) lasting 48-72 h for acute lower limb ischaemia was proposed based on our previous experiences. A retrospective study from June 2016 to December 2020 was conducted to evaluate the efficacy and safety of this protocol. The target lesion revascularisation, amputation and death were also monitored during follow-up. The Kaplan-Meier estimator was used for the subgroup analysis, and univariate and multivariate Cox regression analysis was applied to identify risk factors for reinterventions and death.
RESULTS: 90 lower limbs were involved, including 51 Rutherford Grade I, 35 Grade IIa and four Grade IIb. During a 60.8-h thrombolysis, 86 cases (95.5%) were considered effective according to the angiogram. No major bleeding complication occurred during thrombolysis, and one amputation occurred after. Freedom from target lesion revascularisation, amputation and death were 75.6%, 94.4% and 91.1% during a mean 27.5-month follow-up, respectively. According to the Kaplan-Meier estimator, aortoiliac lesions had lower reintervention rates than femoropopliteal lesions (Log-rank p = 0.010), and cases without narrowing atheromatous plaque had a lower reintervention rate (Log-rank p = 0.049). Age was an independent risk factor for death (p = 0.038, hazard ratio 1.076, 95% confidence interval 1.004-1.153).
CONCLUSIONS: The single-centre protocol of catheter-directed thrombolysis we proposed for acute lower limb ischaemia was effective and safe. Strict blood pressure control during catheter-directed thrombolysis ensured safety. Aortoiliac lesions and cases without narrowing atheromatous plaque had lower reintervention rates during follow-up.
The present invention relates to cilostazol solid dispersion which contains active ingredients of cilostazol and carriers used as dispersing agents. The present invention is characterized in that material of the carrier is selected from one kind or a mixture of several kinds of crospovidone, polyvinylpyrrolidone, polyethyleneglycol 4000, polyethyleneglycol 6000, cyclodextrin, derivative of cyclodextrin, lactose and microcrystalline cellulose, wherein the crospovidone or a mixture of the crospovidone and other carriers is better, and the crospovidone is preferable. The range of the weight ratio of the carrier to medicine is from 0.5 to 20:1 in general, the range is from 1 to 5:1 better, and the range is 1.5:1 best. The cilostazol solid dispersion is prepared in a polishing method. The obtained solid dispersion can be prepared into cilostazol tablets in a direct compression method, a wet granulation compression method and a dry granulation compression method. The present invention can obviously enhance the dissolvability of the medicine and can promote absorption. Therefore, the dissolution and the biological availability of the medicine are greatly enhanced.
Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
Topiramate increases the risk of kidney stones. During adjunctive epilepsy trials, the risk for kidney stones in topiramate-treated adults was 1.5%, an incidence about 2 to 4 times greater than expected in a similar, untreated population. As in the general population, the incidence of stone formation among topiramate-treated patients was higher in men. Kidney stones have also been reported in pediatric patients taking topiramate for epilepsy or migraine. During long-term (up to 1 year) topiramate treatment in an open-label extension study of 284 pediatric patients 1 to 24 months old with epilepsy, 7% developed kidney or bladder stones. Topiramate is not approved for treatment of epilepsy in pediatric patients less than 2 years old [see Use in Specific Populations (8.4)]. 

Topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors can promote stone formation by reducing urinary citrate excretion and by increasing urinary pH [see Warnings and Precautions (5.4)]. The concomitant use of topiramate with any other drug producing metabolic acidosis, or potentially in patients on a ketogenic diet, may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided. 

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation. 

An increase in urinary calcium and a marked decrease in urinary citrate was observed in topiramate -treated pediatric patients in a one-year active-controlled study [see Use in Specific Populations (8.4)]. This increased ratio of urinary calcium/citrate increases the risk of kidney stones and/or nephrocalcinosis.
The present invention relates to a customized diet control system and method through a nutrient combination ratio. The system comprises: a web server that includes a user information input unit, a calorie calculation module, a food ingredient selection module, a diet combination module, and a nutritionist contact module; a database that manages the data of recommended carbohydrate foods, recommended protein foods, recommended lipid foods, dairy products, vegetables, dietary tables, and nutritionist information; and a terminal that is connected to the Internet and runs an application capable of accessing the web server to extract and input information. The nutrient combination ratio of carbohydrate, protein, and lipid on a daily basis is composed of 2 : 2 : 6. The method provides a recommended food list that subdivides representative foods for each nutrient and has a list thereof. By matching with the recommended food list, the method classifies a recommended daily amount for each food and a daily recommended calorie included in the recommended amount. The recommended daily amount is composed of the recommended daily amount of carbohydrates, the recommended daily amount of protein, and the recommended daily amount of lipids for each nutrient, and the recommended daily calorie is divided into the recommended daily carbohydrate calorie, the recommended daily protein calorie, and the recommended daily lipid calorie. Through a diet composed of the recommended daily calories, a combination of recommended foods containing essential nutrients is presented so that the general public can meet the nutrient intake criteria without complicated calculation of nutritional value. By supplying essential energy sources and providing a balanced diet, diseases that may occur due to excessive amounts and unbalanced eating habits can be prevented and the probability of diseases can be minimized, thereby reducing social and economic costs and significantly improving the quality of life.
This post-market clinical follow-up study will be a retrospective data comparison study of a series of Agluna® treated and untreated METS™ modular prostheses conducted at the Royal National Orthopaedic Hospital, Stanmore. The expected sample size will be 106, with 53 patients in each treatment arm (Agluna® treated vs untreated). However there will be an initial pilot of 20 subjects to evaluate the feasibility of the study conduct and to identify if any further study design modification are required.

The primary outcome is the estimation of the infection rate over 12 months following an Agluna (silver) treated METS™ endoprosthetic surgery. This will be compared to the infection rate of non-Agluna Treated devices in a similar population. Incidence of infection will be measured according to the accepted definition of periprosthetic joint infection from the American Academy of Orthopedic Surgeons. The study follow up period is 12 months after implantation. Secondary objectives are to examine the health economic impacts of using the Agluna® Treated METS™ Modular Tumour System in comparison to the untreated METS™ Modular Tumour System and to establish clinically relevant superiority of the Agluna® Treated METS™ Modular Tumour System in comparison to untreated METS™ Modular Tumour System.
The study's aim is to access the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare, in order to improve linkage-to-care among Greek substance users. Underserved populations, such as people who inject drugs (PWID) have limited access to healthcare and a potential solution to expanding healthcare access points is telemedicine. For the past decade, the investigators have studied the efficacy of a facilitated telemedicine model for hepatitis C virus (HCV) treatment integrated into opioid treatment programs (OTPs) for PWIDs. The investigators have achieved high rates of HCV resolution and high patient-satisfaction through facilitated telemedicine. The investigators now seek to explore whether this same intervention might be feasible and acceptable in Greece. The first step is to capture and explore the current knowledge, experiences, believes, perceptions and attitudes of PWID in Greece regarding internet and social media usage and telemedicine concept, through targeted Focus Group Discussions (FGDs) and administration of cross-sectional questionnaire. The perceptions for high-quality healthcare, confidentiality, privacy and security matters will also be explored as well as further relevant attributes.
INTRODUCTION: Parathyroidectomy is recommended for severe secondary hyperparathyroidism (SHPT) due to end-stage kidney disease (ESKD), but surgery is underutilized. High quality and accessible online health information, recommended to be at a 6th-grade reading level, is vital to improve patient health literacy. This study evaluated available online resources for SHPT from ESKD based on information quality and readability.
METHODS: Three search engines were queried using the terms "parathyroidectomy for secondary hyperparathyroidism," "parathyroidectomy kidney/renal failure," "parathyroidectomy dialysis patients," "should I have surgery for hyperparathyroidism due to kidney failure?," and "do I need surgery for hyperparathyroidism due to kidney failure if I do not have symptoms?" Websites were categorized by source and origin. Two independent reviewers determined information quality using JAMA (0-4) and DISCERN (1-5) frameworks, and scores were averaged. Cohen's kappa evaluated inter-rater reliability. Readability was determined using the Flesch Kincaid Reading Ease, Flesch Kincaid Grade Level, and Simple Measure of Gobbledygook tools. Median readability scores were calculated, and corresponding grade level determined. Websites with reading difficulties >6th grade level were calculated.
RESULTS: Thirty one (86.1%) websites originated from the U.S., with most from hospital-associated (63.9%) and foundation/advocacy sources (30.6%). The mean JAMA and DISCERN scores for all websites were 1.3 ± 1.4 and 2.6 ± 0.7, respectively. Readability scores ranged from grade level 5-college level, and most websites scored above the recommended 6th grade level.
CONCLUSIONS: Patient-oriented websites tailoring SHPT from ESKD are at a reading level higher than recommended, and the quality of information is low. Efforts must be made to improve the accessibility and quality of information for all patients.
Cerebral palsy (CP) is a well-recognized neurodevelopmental condition beginning in early childhood and persisting throughout the lifetime. Motor disorders are often accompanied by disturbances of sensation, cognition, communication, perception, behavior, and seizures The activities of daily living and social participation are limited in children with CP due to motor dysfunction, this greatly influences the CP patient's quality of life, and return to society.

Western conventional treatment of CP is multi-professional rehabilitation. In China, CP rehabilitation mainly develops the clinical mode of combining traditional Chinese medicine and western medicine. Acupuncture use as a complementary or alternative therapy has increased worldwide and has become widely applied to CP rehabilitation, which confirms that the efficacy of acupuncture can have a great impact on CP management. Many studies have shown that scalp acupuncture has a remarkable treatment efficacy on motor dysfunction in children with CP in China. But, Although acupuncture as a treatment for cp has become widely accepted and showed better clinical curative effect than conventional treatments, a Meta-Analysis published in 2018 based on clinical randomized controlled trials summarized that the clinical curative effect of acupuncture treatment in children with CP remains uncertain due to the small number of randomized controlled trials available and the small sample sizes. More high-quality and large-scale studies are still needed. The purpose of this study is to observe the therapeutic effect of scalp acupuncture treatment for motor dysfunction in children with CP by using the international general evaluation scales.

In this 12-week, assessor-blind, randomized, controlled study of scalp acupuncture as additional treatment with the rehabilitation treatment, a total of 76 children with cerebral palsy will be recruited. The patients will be randomly assigned to two different groups: 1) the treatment group and 2) the control group. The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks, and the control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks. Both groups will be evaluated at baseline, week4 (treatment 12), week 8 (treatment 24), week12(treatment 36) and week 24(follow-up) using GMFM scale, FMFM scale, PEDI scale and CP-QOL scale. The study will be conducted at Children's Hospital of Fudan University.
The invention is a composition for duck spleen necrosis control, belonging to veterinary medicines. The composition is mainly formed by compounding white atratylodes rhizome, medicated leaven, white peony root, jujube, poria, atractylodes, pinellia rhizome, dried ginger and other Chinese medicinal herbs serving as basic materials, with a liver-protective and choleretic drug taurine, an immunopotentiating drug glutamine and the like serving as companies. the weight ratio of each active ingredient is as follows: 15% of white atratylodes rhizome, 12% of medicated leaven, 15% of white peony root, 10% of jujube, 12% of poria, 10% of atractylodes, 8% of pinellia rhizome, 12% of dried ginger, 5% of taurine, and 1% of glutamine. This veterinary composition is used for the treatment of duck spleen necrosis diseases. The process method for the composition comprises: grinding, drying, and screening each of the Chinese medicinal herbs (white atratylodes rhizome, medicated leaven, white peony root, jujube, poria, atractylodes, pinellia rhizome, dried ginger), weighing accurately according to the required ratio, then adding each of the Western medicines ingredients (taurine and glutamine) according to the required ratio, mixing for 30min, performing quality tests to semi-finished products, sub-packaging, packaging, performing quality tests to finished products, and putting into storage. The application method of the composition is mixing the composition at a ratio of 0.5% with feed, and feeding ducks for 3-5 consecutive days as a course. The composition of the present invention has high sensitivity to duck spleen necrosis, good effect, low resistance, convenient for use, and good promotion and application values.
The web-based digital story preparation process will be completed as a 3-5 minute short film by using pictures, videos, voiceovers and various video editing techniques by the researcher trained in storytelling. The digital story will be prepared in an appropriate format, taking into account the cognitive development and period characteristics of school children (7-12 years old).
Mirtazapine tablets, USP are an orally administered drug. Mirtazapine, USP has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c] benzazepine and has the molecular formula of C17H19N3. Its molecular weight is 265.36. The structural formula is the following and it is the racemic mixture:

Structural Formula:

Mirtazapine, USP is a white to creamy white crystalline powder which is slightly soluble in water. Mirtazapine tablets, USP are supplied as scored tablets containing 15 mg or 30 mg of mirtazapine, USP, and unscored tablets, USP containing 7.5 mg or 45 mg of mirtazapine, USP.

Each tablet contains lactose monohydrate, corn starch, pregelatinized starch, colloidal silicon dioxide, magnesium stearate. Opadry 20A colorants contain the following inactive ingredients: The 7.5 mg and 15 mg tablets are coated with a yellow colored film (opadry 20A52767) that is made of iron oxide yellow, hydroxypropyl cellulose, hypromellose 2910 and titanium dioxide. The 30 mg tablets are coated with a reddish brown colored film (opadry 20A56666) that is made of iron oxides yellow, red and black, hydroxypropyl cellulose, hypromellose 2910 and titanium dioxide. The 45 mg tablets are coated with a white colored film (opadry 20A58916) that is made of hydroxypropyl cellulose, hypromellose 2910 and titanium dioxide.
An insulin analogue contains a foreshortened B-chain polypeptide lacking residues B1-B3 and optionally contains an additional substitution in the C-terminal B23-B30 segment of the B-chain. The insulin analogue lacking residues B1-B3 may contain substitutions at B28 and/or B29 that confer rapid action and optionally a non-standard substitution at B24. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis is provided using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.
After screening all patients will be randomized in 1:1 ratio to either placebo group or study group (receiving L-C for 8-weeks). Randomization will stratify patients by: age, sex, BMI and severity of OSA. Randomized patients will receive orally either placebo or L-C once a day for 8-weeks. All supplements will be packed in a white box. Because this is a double-blind study, vial labels will contain a unique identification number that will not disclose to the patient or investigator if L-C or matching placebo is included. The daily amount of L-C will be 1400 mg. The detailed composition of the product will be assessed. All patients will receive a test product during the control visits once a month and will be asked to take it once a day in the morning. The completion of the data will be checked during the visits and also via telephone while the study is conducted. All concomitant medications used (including herbal supplements) will be recorded in electronic database. The patients will be asked to continue their habitual diet. Moreover, they will be also advised that they are free to withdraw from participation in this study at any time, for any reason, and without prejudice. The reason for withdrawal and the date of discontinuation will be recorded in our database. Any Adverse Event (AE) will be recorded according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE), clinically significant AE, severe laboratory abnormality, intercurrent illness, or other medical condition that indicates that continued administration of study medication is not in the best interest of the patient.

The treatment will be administrated under supervision of experienced nutritionist and medical doctor. The anthropometrical and biochemical measurements with assessment of diet, quality of life and sleep will be completed by the patients at each of the study visits, which will take place at the baseline (screening visit), after 4 weeks, in the post-intervention period (week 8) and at a 6-month follow-up.
Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
Coronavirus disease 2019 (COVID-19) is a type of pneumonia caused by the SARS-CoV-2 coronavirus. It can cause acute pulmonary and systemic inflammation, which can lead to death in severely ill patients. This study explores the potential reasons behind severe COVID-19 and its similarities to systemic autoimmune diseases. This study reviewed unbiased high-throughput gene expression datasets, including next-generation and single-cell RNA sequencing. A total of 27 studies and eight meta-analyses were reviewed. The studies indicated that severe COVID-19 is associated with the upregulation of genes involved in pro-inflammatory, interferon, and cytokine/chemokine pathways. Additionally, changes were observed in the proportions of immune cell types in the blood and tissues, along with degenerative alterations in lung epithelial cells. Genomic evidence also supports the association of severe COVID-19 with various inflammatory syndromes, such as neuronal COVID-19, acute respiratory distress syndrome, vascular inflammation, and multisystem inflammatory syndrome. In conclusion, this study suggests that gene expression profiling plays a significant role in elucidating the etiology of severe COVID-19.
Xanthogranulomatous inflammation is a chronic inflammatory reaction microscopically characterized by aggregation of foamy histiocytes, fibrous tissue, and infiltration of various inflammatory cells. In contrast to xanthogranulomatous inflammation in the gallbladder or kidney, xanthogranulomatous pancreatitis is rare. We herein present a case of xanthogranulomatous pancreatitis in a patient who underwent distal pancreatectomy with splenectomy under preoperative suspicion of a pancreatic pseudocyst or pancreatic tumor. A 77-year-old woman with a 1 month history of epigastric pain, anorexia, and general fatigue was admitted to our hospital. Contrast-enhanced computed tomography revealed a cystic mass with ill-defined margins at the pancreatic tail together with a splenic abscess. Contrast-enhanced endoscopic ultrasound detected a hyperechoic cystic lesion at the tail of the pancreas with heterogeneous internal echogenicity, and part of the intra-cystic content was enhanced by the contrast agent. Endoscopic retrograde cholangiopancreatography showed a cystic lesion at the tail of the pancreas that continued into the main pancreatic duct, and the main pancreatic duct was slightly narrowed downstream of the cystic lesion. Pancreatic juice cytology revealed suspicious cells, leading to the possibility of intraductal papillary mucinous carcinoma. Distal pancreatectomy with splenectomy was performed, and the histopathological diagnosis was xanthogranulomatous pancreatitis with no malignant findings.